Skip to content
Peptigraph home

Peptides for Weight loss

The peptides people most often research for weight loss, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
8
With human trials
8
FDA approved (any use)
5
Searches per month
150,190
Showing 8 peptides · ordered by search interest for this goal
  1. SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40934115Human1978Animal160Summarised14FDA approved (Ozempic, Wegovy, Rybelsus)For weight lossOverview
  2. TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4Arthritis & rheumatology 2026, PMID 41903163Human990Animal49Summarised16FDA approved (Mounjaro, Zepbound)For weight lossOverview
  3. RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954Human71Animal7Summarised13Investigational · phase 3For weight lossOverview
  4. SermorelinGHRH analogHuman observational evidence, 3 of 4Metabolism: clinical and experimental 1997, PMID 9005976Human4Animal0Summarised1Compounded by prescriptionFor weight lossOverview
  5. hCGGonadotropinHuman RCT evidence, 4 of 4The Journal of clinical endocrinology and metabolism 2002, PMID 12107212Human156Animal124Summarised5FDA approved (prescription only)For weight lossOverview
  6. OrforglipronOral small-molecule GLP-1 agonistHuman RCT evidence, 4 of 4Lancet 2026, PMID 41275875Human55Animal0Summarised9FDA approved (Foundayo, Apr 2026)For weight lossOverview
  7. CJC-1295GHRH analogHuman observational evidence, 3 of 4Substance use & misuse 2016, PMID 26771670Human2Animal1Summarised1Not FDA approved · research chemicalFor weight lossOverview
  8. MOTS-cMitochondrial-derived peptideHuman RCT evidence, 4 of 4Scientific reports 2021, PMID 34413391Human12Animal13Summarised4PCAC voted 7–5 for 503A (Jul 2026)For weight lossOverview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.
Related goals

Explore nearby goals

What people search

  • fat loss peptides135,000/mo
  • best peptides for fat loss12,100/mo
  • peptide injections for weight loss1,600/mo
  • peptide therapy for weight loss880/mo
  • peptide stack for fat loss390/mo
  • peptide therapy for fat loss210/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  2. 2Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  3. 3Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
  4. 4Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  5. 5A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency.The Journal of clinical endocrinology and metabolism · 2002PMID 12107212Accessed 2 Oct 2026
  6. 6Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  7. 7Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse · 2016PMID 26771670Accessed 2 Oct 2026
  8. 8Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026

Found an error? Report a correction.